Key Takeaways
- Strong quarter, guidance raised: Revenue grew 24.1% YoY to ₹306.2 crores, and EBITDA margin guidance was lifted to 28–30% for FY26, driven by a deliberate portfolio restructuring toward higher-margin products.
- Portfolio churn is the margin engine: Management is actively churning out low-margin pharma intermediates, a move that expanded gross margin by 1,232 bps YoY and is described as a permanent structural improvement.
- New verticals are funded but not yet contributing: Capex for electrolyte additives and a Korean JV is underway, with revenue expected from Q4 FY26 and H2 FY27 respectively, while semiconductor chemicals remain a medium-term story.
- CDMO pipeline is progressing, but visibility is short: Validation batches have been dispatched and the pipeline is expanding, yet management declined to quantify the opportunity size or provide a multi-year growth outlook for the segment.
- What to watch next quarter: Whether the 25% full-year growth guidance holds after 21% H1 delivery, the pace of capacity utilization ramp at the new CDMO block, and any update on the stalled electrolyte additive JV.
Revenue Growth & Segment Performance
- Pharma intermediates drove the quarter: The Advanced Pharmaceutical Intermediates segment grew 27.1% YoY to ₹262.6 crores, powered by the CDMO business and a healthy contribution from the core portfolio.
- Specialty chemicals were stable but mixed: Revenue of ₹43.6 crores grew 7.3% YoY, with commodity chemicals delivering strong volume-led growth while the Baba Fine Chemicals business was softer.
- H2 needs to accelerate: After delivering 21% growth in H1, the company must deliver a stronger H2 to hit its 25% full-year target, a gap management says will be filled by the CDMO pipeline and newer chemical verticals.
- Traditional spec-chem growth is capped: Management expects the traditional specialty chemicals business to grow only 10–15% going forward, framing the newer verticals as the necessary growth accelerant.
Naresh Patel: "Together, these 2 verticals, battery chemicals and semiconductors will serve as important growth pillar for us alongside our CDMO business, where we are witnessing a healthy increase in customer enquiries and new molecule additions to our CDMO pipeline."
Margin Structure & Sustainability
- Gross margin jumped on product mix, not just operating leverage: The 1,232 bps YoY expansion to 55.8% came from churning out low-margin pharma intermediate products and improving margins in top revenue-contributing products, plus a 2.5% operational efficiency gain including the new solar plant.
- Management calls the improvement permanent: The margin uplift is described as a function of product mix and structural cost improvements, not a cyclical tailwind, giving management confidence to raise FY26 EBITDA margin guidance to 28–30%.
- Electrolyte additives will dilute the margin profile: Management confirmed the new electrolyte additives business will not carry 30%+ EBITDA margins, though it declined to specify whether margins fall in the 15–20% range.
- Working capital tightened sharply: Working capital days improved by 28 days sequentially to 100 days, driven by better inventory and debtor days, with a full-year target of 95–105 days.
Abhishek Patel: "We have slowly started redefining our product portfolio in such a way that we churn out some of the low-margin products and focus on something, which is more sustainable and with a sustainable revenue growth."
CDMO Business & Pipeline
- Validation batches mark progress: A couple of validation batches for new CDMO products were dispatched during the quarter, an important step toward commercial scale, with revenue expected by end-FY26 subject to regulatory approvals.
- Business is sequential, not lumpy: CDMO revenue is typically lowest in Q1 and builds sequentially through Q4, and management claims full-year visibility based on customer requirements.
- Capacity is ready, utilization will take time: Block 3 of the CDMO plant at Ankleshwar is operational but running at only 38% utilization, with a two-year timeline to reach optimum levels.
- Competitive positioning rests on compliance credentials: Management pointed to its EcoVadis Platinum certification (top 1% globally) as the moat that wins CDMO business, but declined to provide a specific growth outlook or market size when asked.
Abhishek Patel: "We now are EcoVadis Platinum certified company, which is only 1% of the companies over the world are into this territory. So this gives us the confidence that because of this, we are able to sustain -- in fact, get a good share of this business in the market."
New Verticals: Battery, Semiconductor & Korea
- Electrolyte additive capex is nearly done: The Jaghadia plant for VC and FEC is expected to complete by Q4 FY26, with a minor delay from the extended rainy season; production will start immediately and contribute meaningfully in FY27.
- The plant is export-only and will ramp slowly: The 2,000-metric-ton capacity is entirely for export customers, and management expects a three-year ramp to optimum utilization.
- Korean JV (Indichem) broke ground: The groundbreaking ceremony occurred last month, with Acutaas holding a 75% investment stake and the Korean partner contributing technology, market access, and starting material; commercial revenue is expected from H2 FY27.
- Semiconductor chemicals are a medium-term bet: Engagement with customers in Korea, Japan, and Taiwan is progressing through Baba Fine Chemicals, with a couple of products expected to move to commercial scale, but meaningful revenue contribution is some time away.
- One electrolyte JV remains stalled: A separate JV formed last year to produce electrolyte has not progressed, with management calling it "status quo only" and offering no timeline.
Competitive Position & Strategy
- Chemistry-driven diversification is the thesis: Management frames the move from pharma into battery, semiconductor, and specialty chemicals as a natural extension of its chemistry capabilities, not a departure from core competence.
- Market share is concentrated in top products: For most of its top products, the company claims 50–80% market share against any competitor, a statistic offered as evidence of long-term competitive staying power.
- Diversification mitigates customer risk: The company maintains multiple products per customer and multiple customers per product, with no single product going to a single customer, though management did not directly answer a question about concentration risk.
- Chinese competition is a known threat, but details are withheld: Management declined to comment on how it will compete with Chinese producers whose EBITDA and gross margins are in single digits, calling it outside its ability to assess.
Naresh Patel: "We are a very strong chemistry-driven company. So basically, chemistry don't have an application only in pharma. So we want to expand our chemistry base out of pharma, and that's why we started acquiring Gujarat Organics and then we entered into the battery and then later on, we acquired Baba and now we enter into the semicon."
Capex, Capacity & Balance Sheet
- Growth capex is largely complete: Management stated that all capex required for growth through FY28 is already done, with future spending expected to be maintenance capex only.
- Capacity utilization has room to run: The specialty chemicals block at Jaghadia is at 52% utilization, and Block 3 of the CDMO plant is at 38%, leaving significant headroom before new capex is needed.
- Goodwill arose from the Korea investment: A goodwill charge of approximately ₹16 crores was recorded this quarter, reflecting a premium paid on the non-controlling stake in Indichem.
- Solar power is partly online: A 5-megawatt solar plant was commissioned this quarter, part of a total 16-megawatt project that contributes to operational efficiency gains.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Around 25% for FY26 | FY26 full year |
| EBITDA margin | 28–30% range (raised from prior guidance) | FY26 full year |
| Electrolyte additive production | Commence at Jaghadia plant | Q4 FY26 |
| CDMO new product revenue | Start contributing, subject to regulatory approval | End of FY26 |
| Indichem Korea JV revenue | Commercial revenue begins | H2 FY27 |
| Block 3 CDMO capacity utilization | Reach optimum level | Within 2 years |
| Electrolyte additive capacity ramp | Reach optimum utilization | ~3 years from start |
| Working capital days | 95–105 days | FY26 full year |
| Traditional spec-chem growth | 10–15% growth territory | By end of FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹306.2 cr, +24.1% YoY |
| H1 FY26 revenue | ₹513.4 cr, +21.3% YoY |
| Gross profit | ₹170.7 cr, +59.3% YoY |
| Gross margin | 55.8%, expanded 1,232 bps YoY |
| EBITDA | ₹95.3 cr, grew almost 2x YoY |
| EBITDA margin | 31.1%, up 1,130 bps YoY |
| PAT | ₹71.9 cr, +91.3% YoY |
| PAT margin | 23.5%, expanded 824 bps YoY |
| FY26 revenue growth guidance | ~25% |
| FY26 EBITDA margin guidance | 28% to 30%, revised upward |
| Pharma Intermediates segment revenue | ₹262.6 cr, +27.1% YoY |
| Specialty Chemicals segment revenue | ₹43.6 cr, +7.3% YoY |
| Net cash and cash equivalents | ₹240.6 cr as of Sep 30, 2025 |
| Working capital days | 100 days, improved 28 days QoQ |
| H1 FY26 capex | ₹141 cr, full-year plan ~₹250 cr |
| Trade receivables days | 87 days |
| Specialty Chemicals capacity utilization (Jaghadia) | 52% |
| CDMO Block 3 capacity utilization (Unit 2) | 38% |